Dilutol HTA 2.5 mg tablets

Package leaflet: Information for the user

Introduction

Package leaflet: information for the user

Dilutol HTA 2.5 mg tablets

Torasemide

Read the entire leaflet carefully before you start taking this medicine because it contains important information for you.

• Keep this leaflet as you may need to read it again.
• If you have any questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only and must not be given to other people, even if they have the same symptoms, as it may harm them.
• If you experience any adverse effects, consult your doctor or pharmacist, even if they are not listed in this leaflet. See section 4.

Leaflet contents

1. What Dilutol HTA 2.5 mg tablets are and what they are used for.
2. What you need to know before taking Dilutol HTA 2.5 mg tablets.
3. How to take Dilutol HTA 2.5 mg tablets.
4. Possible side effects.

5 Storage of Dilutol HTA 2.5 mg tablets.

1. Contents of the pack and other information.

1. What Dilutol HTA 2.5 mg tablets are and what they are used for

DILUTOL HTA 2.5 mg contains torasemide, which belongs to a group of medicines called antihypertensive diuretics.

DILUTOL HTA 2.5 mg is indicated for the treatment of essential arterial hypertension.

2. What you need to know before taking Dilutol HTA 2.5 mg tablets

Do not take Dilutol HTA 2.5 mg

• If you are allergic to torasemide, sulfonylureas (medicines used to treat diabetes), or any of the other ingredients of this medicine (listed in section 6).
• If you have anuria (absence of urine production) due to kidney failure.
• If you have severe impairment of liver function.

Warnings and precautions

Talk to your doctor or pharmacist before starting to take Dilutol HTA.

• During long-term treatment, and especially in elderly patients, your doctor will periodically perform blood tests to monitor various parameters such as potassium, glucose, uric acid, creatinine, and lipids.
• Urinary retention should be corrected before and during treatment with this medicine.
• If you have a kidney disease, it must be treated.
• If you have a severe liver disease, especially if it has affected the brain.
• This medicine may affect muscle cells of the heart, skeleton, and intestine. Potassium levels should be monitored during treatment with this medicine.
• Sodium levels should be monitored before or during treatment.
• In patients with reduced blood volume, this medicine should be administered under medical supervision.
• If you have hypotension, it should be corrected before or during treatment with this medicine.
• If you have arrhythmias, blood tests should be performed to monitor levels of sodium, potassium, calcium, and magnesium.
• If you have gout (accumulation of uric acid in the body).
• If you are allergic to sulfonamides.

Children

Since the safety and efficacy of torasemide have not been established in children (<18 years), its use is not recommended in this population group.

Use in elderly patients

No differences in efficacy or safety have been observed according to patient age.

Use of Dilutol HTA 2.5 mg with other medicines

Inform your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines.

You should also inform your doctor if you are taking any of the following medicines, which may interact with torasemide:

• Cardiac glycosides such as digoxin (a medicine for the heart), which may have increased adverse effects.
• Antidiabetic medicines, whose action may be reduced.
• Antibiotics of the aminoglycoside group, platinum-derived cytostatics such as cisplatin (a medicine for cancer treatment), and cephalosporins: may increase kidney or ear toxicity.
• Salicylates, as they may increase the risk of gout attacks.
• Coumarin derivatives.
• Non-steroidal anti-inflammatory drugs (e.g., ibuprofen, indometacin), which may reduce the effect of diuretics and increase the risk of kidney failure.
• Antihypertensives (particularly ACE inhibitors), which may cause hypotension and increase the risk of kidney failure.
• Probenecid, which may reduce the effect of torasemide.
• Muscle relaxants and theophylline.
• Lithium, since torasemide may increase the adverse effects of lithium.
• Cholestyramine (a medicine used to lower blood cholesterol levels): may reduce the effect of torasemide.

Taking Dilutol HTA 2.5 mg with food and drink

The tablets may be taken with or without food. They should be swallowed whole with some liquid, preferably in the morning.

Pregnancy, breastfeeding, and fertility

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to become pregnant, consult your doctor or pharmacist before using any medicine.

The use of torasemide is not recommended during pregnancy or in women who are breastfeeding, as it is unknown whether torasemide passes into breast milk.

Driving and using machines

This medicine may affect your ability to drive or operate machinery, especially if taken concomitantly with alcohol.

Dilutol HTA 2.5 mg contains lactose.

If your doctor has informed you that you have an intolerance to certain sugars, consult with him before taking this medicine.

3. How to take Dilutol HTA 2.5 mg tablets

Follow exactly the instructions for use of this medicine as given by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist.

Remember to take your medicine.

These tablets may be taken at any time in relation to meals, as convenient. Swallow them whole with some liquid, preferably with breakfast.

Your doctor will determine the duration of your treatment with Dilutol. Do not stop treatment earlier, as your condition may worsen.

The recommended dose in adults is:

In hypertension: The usual initial dose is 2.5 mg to 5 mg once daily. However, your doctor may increase this up to 10 mg per day or prescribe an additional antihypertensive agent.

If you take more Dilutol HTA 2.5 mg than you should

In case of overdose or accidental ingestion, contact your doctor or pharmacist immediately, go to the nearest hospital, or call the Toxicology Information Service at telephone (91) 562 04 20, indicating the medicine and the amount ingested. It is recommended to bring the medicine's packaging and leaflet to the healthcare professional.

In case of overdose, increased urine output may occur, along with drowsiness, confusion, weakness, and dizziness.

If you forget to take Dilutol HTA 2.5 mg

Do not take a double dose to make up for the missed dose.

Take the missed dose as soon as you remember. The next day, resume taking the medicine at your usual time.

If you have any further questions about the use of this medicine, ask your doctor or pharmacist.

4. Possible adverse effects

Like all medicines, this medicine can cause adverse effects, although not everyone experiences them.

Adverse effects may occur with the following frequencies:

Very common: affects more than 1 in 10 treated patients.

Common: affects between 1 and 10 in every 100 treated patients.

Uncommon: affects between 1 and 10 in every 1,000 treated patients.

Rare: affects between 1 and 10 in every 10,000 treated patients.

Very rare: affects fewer than 1 in every 10,000 treated patients.

Frequency not known: cannot be estimated from available data.

The following adverse effects have been reported:

Common:

Increase in blood pH (metabolic alkalosis), electrolyte and fluid imbalance (e.g. decreased total blood volume, decreased sodium and/or potassium in blood), headache, dizziness, gastrointestinal disturbances (e.g. loss of appetite, abdominal pain, nausea, vomiting, diarrhea, constipation), muscle spasms, fatigue, tiredness.

Uncommon:

Increase in liver enzymes, urinary retention, gallbladder enlargement, increased levels of uric acid, glucose, and lipids such as triglycerides or cholesterol in the blood.

Rare:

Increased levels of urea and/or creatinine in the blood.

Very rare:

Skin allergic reactions (itching and skin rashes), photosensitivity reaction.

Frequency not known:

Severe skin reactions (e.g. Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis), decreased number of platelets and/or leukocytes in blood, anemia, cerebral ischemia (reduced blood supply to the brain), sensation of numbness in the body (paresthesia), confusion, visual disturbances, ringing in the ears (tinnitus), deafness, heart attack (acute myocardial infarction), reduced blood supply to the heart (myocardial ischemia), angina pectoris, loss of consciousness (syncope), hypotension, blockage of blood vessels (embolism), dry mouth, inflammation of the pancreas (pancreatitis).

Reporting of adverse effects

If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect not listed in this leaflet. You may also report them directly via the Spanish Pharmacovigilance System for Human Medicines: https://www.notificaram.es . By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. Storage of Dilutol HTA 2.5 mg tablets

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date stated on the packaging after EXP. The expiry date is the last day of the month indicated.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines and packaging you no longer need. This will help protect the environment.

6. Contents of the pack and other information

Composition of Dilutol HTA 2.5 mg tablets

The active substance is torasemide.

The other components are lactose monohydrate, corn starch, colloidal silicon dioxide, and magnesium stearate.

Appearance of the product and contents of the pack

Dilutol HTA 2.5 mg are round, white or almost white tablets. The tablets are presented in PVC-aluminum blisters, and each pack contains 30 tablets.

Marketing Authorization Holder and Manufacturer

Marketing Authorization Holder:

Viatris Healthcare Limited
Damastown Industrial Park
Mulhuddart, Dublin 15
Dublin
Ireland

Manufacturer:

Madaus GmbH
51101 Cologne
Germany

For further information about this medicinal product, please contact the local representative of the Marketing Authorization Holder:

Viatris Pharmaceuticals, S.L.
C/ General Aranaz, 86
28027 - Madrid
Spain

Date of the most recent review of this leaflet: July 2018

Detailed and up-to-date information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (https://www.aemps.gob.es)